Time-restricted eating with or without fiber for weight management in young cancer survivors
Time Restricted Eating with or Without a Fiber Supplement for Weight Management in Pediatric Cancer Survivors
NA · University of Illinois at Chicago · NCT05826184
This study is testing whether time-restricted eating with or without a fiber supplement can help young cancer survivors manage their weight and improve their health.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | University of Illinois at Chicago (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05826184 on ClinicalTrials.gov |
What this trial studies
This study explores the effects of time-restricted eating (TRE) and the addition of a prebiotic fiber supplement on weight management in pediatric cancer survivors aged 18-39. It aims to address obesity and its related health issues, which are prevalent among this population due to treatment-related late effects. The study will assess the safety, feasibility, and acceptability of these interventions, focusing on their potential to improve gut health and reduce cardiometabolic risks. Participants will follow an 8-hour eating window to evaluate the impact on weight and overall health.
Who should consider this trial
Good fit: Ideal candidates are pediatric cancer survivors aged 18-39 with a BMI between 25 and 39.99 kg/m2.
Not a fit: Patients who are under 18 or over 39 years old, or those with a BMI outside the specified range, will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve weight management and long-term health outcomes for pediatric cancer survivors.
How similar studies have performed: While similar approaches have been explored, this specific combination of time-restricted eating and fiber supplementation in pediatric cancer survivors is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-39 years old at time of consent * Completed anti-tumor treatment for pediatric cancer * BMI 25-39.99 kg/m2 * Able to provide (self or guardian) written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. * As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: Subjects meeting any of the criteria below may not participate in the study: * Individuals \<18 or \>39 years of age * Individuals on glucoregulatory medication * Individuals with BMI ≥ 40kg/m2 and \< 25kg/m2 * Individuals who are pregnant, trying to become pregnant or breast feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines at screening as well as prior to all DXA scans. * Shift workers who maintain a work schedule that crosses 12:00 am \> 1 day per week * Individuals with a history of eating disorders * Active infection requiring systemic therapy * Uncontrolled HIV/AIDS or active viral hepatitis * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial. * Other major comorbidity, as determined by study PI * Illicit drug use (excluding self-reported marijuana) or excessive use of alcohol (i.e., \> 2 drinks/day) * Currently participating in Weight Watcher's or another weight loss program with a ≥ 3% weight loss in three months prior to recruitment * History of: Myocardial infarction, Stroke, Congestive heart failure, Chronic hepatitis, Cirrhosis, Chronic pancreatitis * History of solid organ transplantation * Individual does not have access to the Internet * Individuals who have taken antibiotics \< 2 months prior to the initiation of the study * Individuals who regularly use (≥ 3 times per week) prebiotics, probiotics, synbiotics, prebiotic supplements or laxatives within the past month
Where this trial is running
Chicago, Illinois
- University of Illinois at Chicago — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Kelsey Gabel, PhD — UIC
- Study coordinator: Kelsey Gabel, PhD
- Email: kdipma2@uic.edu
- Phone: 312-413-8911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Weight, Body